In Interim Results from Phase 3 Study, Merck’s Investigational Ebola
Vaccine Efficacious; Study is Continuing
Global Collaboration Enabled Vaccine to Move from First-in-Human Studies
to Initial Phase 3 Results Within One Year
KENILWORTH,
N.J., July 31, 2015 -- Merck (known as MSD outside the US and
Canada) said today that its investigational Ebola vaccine candidate,
rVSV-ZEBOV, was found to have 100 percent efficacy in an analysis of interim
data from a Phase 3 ring vaccination trial in Guinea.
Preliminary
conclusions from this study, which is continuing, were published on-line today
in The Lancet.
The authors
report that vaccine efficacy was 100 percent (95% confidence interval: 74.7 -
100%; p=0.0036) following vaccination with a single dose of the rVSV-ZEBOV
vaccine. It appeared that all vaccinated individuals were protected against
Ebola virus infection within 6 to 10 days of vaccination.
Anexo:
0 comentários:
Postar um comentário